Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

HealthRX vs Iron Med RX

Two GLP-1 desks, one scoreboard. We put HealthRX and Iron Med RX head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 7 · Grade B

HealthRX

Visit HealthRX Full brief →
vs
No. 487 · Grade C

Iron Med RX

Visit Iron Med RX Full brief →

The verdict

HealthRX takes this head-to-head.

HealthRX scores 86 to 46 on our six-factor Brief Score — A LegitScript-certified, physician-supervised desk (healthrx.com) whose real hook is breadth: injectable and a rare oral GLP tablet, on both molecules, with transparent no-insurance monthly pricing.

That doesn't make Iron Med RX a bad call — it's best for people who want oral or injectable compounded glp-1 from one provider and don't mind account-gated pricing. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
85
40
Supply Reliability
85
64
Transparency
83
20
Access Breadth
91
36
Clinical Oversight
89
71
Track Record
81
55
HealthRXBrief Score 86 · 46Iron Med RX

Price, coverage & the tracker

HealthRXIron Med RX
Brief Score86/100 (B)46/100 (C)
Semaglutide$189/moNot disclosed
Tirzepatide$349/moNot disclosed
CoverageNot publicly listedCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualYesYes
On the trackerStableprice stableNewnew to the tracker, no prior reading

HealthRX: Company-stated tiers held flat this cycle; the LegitScript badge and a rare oral GLP tablet are the draw, but some tiers are self-reported rather than checkout-verified.

Iron Med RX: New to the tracker on 1 August 2026. This program publishes no monthly medication price, so there is no line for us to track until it does.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.